Clinical applications of PET in brain tumors
W Chen - Journal of nuclear medicine, 2007 - Soc Nuclear Med
Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging
plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate …
plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate …
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods
R Ahmed, MJ Oborski, M Hwang… - Cancer management …, 2014 - Taylor & Francis
Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such …
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such …
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy
W Chen, DHS Silverman, S Delaloye… - Journal of Nuclear …, 2006 - Soc Nuclear Med
We evaluated the amino acid and glucose metabolism of brain tumors by using PET with 3,
4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA) and 18F-FDG. Methods: Eighty-one …
4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA) and 18F-FDG. Methods: Eighty-one …
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
P Workman, EO Aboagye, YL Chung… - Journal of the …, 2006 - academic.oup.com
Clinical trials of new cancer drugs should ideally include measurements of parameters such
as molecular target expression, pharmacokinetic (PK) behavior, and pharmacodynamic (PD) …
as molecular target expression, pharmacokinetic (PK) behavior, and pharmacodynamic (PD) …
18F-FDOPA kinetics in brain tumors
C Schiepers, W Chen, T Cloughesy… - Journal of Nuclear …, 2007 - Soc Nuclear Med
l-3, 4-Dihydroxy-6-18F-fluoro-phenyl-alanine (18F-FDOPA) is an amino acid analog used to
evaluate presynaptic dopaminergic neuronal function. Evaluation of tumor recurrence in …
evaluate presynaptic dopaminergic neuronal function. Evaluation of tumor recurrence in …
L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro …
C Haase, R Bergmann, F Fuechtner… - Journal of Nuclear …, 2007 - Soc Nuclear Med
Expression of system L amino acid transporters (LAT) is strongly increased in many types of
tumor cells. The purpose of this study was to demonstrate that 18F-labeled amino acids, for …
tumor cells. The purpose of this study was to demonstrate that 18F-labeled amino acids, for …
Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma
B Beuthien-Baumann, A Strumpf, J Zessin… - European journal of …, 2007 - Springer
Purpose In patients with medullary thyroid carcinoma (MTC), rising levels of the tumour
markers calcitonin and CEA after primary surgery indicate tumour recurrence or metastases …
markers calcitonin and CEA after primary surgery indicate tumour recurrence or metastases …
[HTML][HTML] Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of …
M Sinigaglia, T Assi, FL Besson, S Ammari, M Edjlali… - EJNMMI research, 2019 - Springer
Immunotherapies that employ immune checkpoint modulators (ICMs) have emerged as an
effective treatment for a variety of solid cancers, as well as a paradigm shift in the treatment …
effective treatment for a variety of solid cancers, as well as a paradigm shift in the treatment …
Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma
Introduction Despite radical treatment therapies, glioma continues to carry with it a uniformly
poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) …
poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) …
[HTML][HTML] Current radiopharmaceuticals for positron emission tomography of brain tumors
J Jung, BC Ahn - Brain tumor research and treatment, 2018 - ncbi.nlm.nih.gov
Brain tumors represent a diverse spectrum of histology, biology, prognosis, and treatment
options. Although MRI remains the gold standard for morphological tumor characterization …
options. Although MRI remains the gold standard for morphological tumor characterization …